{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:52:55Z","timestamp":1791831175822,"version":"4.3.4"},"reference-count":124,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"crossref","award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"crossref"}]},{"award":["P2022\/BMD-7321"],"award-info":[{"award-number":["P2022\/BMD-7321"]}],"id":[{"id":"https:\/\/ror.org\/040scgh75","id-type":"ROR","asserted-by":"publisher"}]},{"name":"ProACapital"},{"name":"HALEKULANI"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metastatic triple-negative breast cancer (mTNBC) remains one of the most challenging therapeutic settings in oncology. Although it has traditionally been defined by the absence of hormone receptor expression\u2014estrogen receptor (ER) and progesterone receptor (PR)\u2014and HER2 amplification or overexpression, this simplified definition fails to capture the biological complexity that drives its marked clinical heterogeneity, therapeutic resistance, and prognostic variability. Over the past decade, multiple studies have challenged the notion of TNBC as a single disease entity, identifying distinct molecular subtypes, including Basal-like 1 (BL1), Basal-like 2 (BL2), Mesenchymal (M), Mesenchymal Stem-like (MSL), Immunomodulatory (IM), and Luminal Androgen Receptor (LAR), each characterized by specific biological programs and therapeutic vulnerabilities. In parallel, clinically oriented systems such as the Fudan classification have enabled the prospective evaluation of subtype-guided therapeutic strategies in metastatic disease, as illustrated by the FUTURE and FUTURE-SUPER trials. In this review, we examine the molecular classification and clinical behavior of mTNBC subtypes, integrating genomic, transcriptomic, epigenetic, immunologic, stromal, and biomechanical dimensions of tumor heterogeneity. We also discuss emerging tools, including single-cell RNA sequencing, spatial transcriptomics, circulating tumor DNA analysis, long non-coding RNA profiling, and surrogate immunohistochemistry-based classifiers, as well as their potential role in refining patient stratification. From a therapeutic perspective, we review subtype-guided strategies involving chemotherapy, platinum agents, PARP inhibitors, immunotherapy, antiandrogen therapy, PI3K\/AKT\/mTOR pathway inhibition, antiangiogenic approaches, and antibody\u2013drug conjugates. Redefining mTNBC through biologically driven stratification represents a rational strategy to optimize treatment selection, support clinical trial design, and accelerate the development of precision oncology approaches. However, clinical implementation requires greater methodological standardization, validated predictive biomarkers, accessible diagnostic platforms, and dynamic monitoring strategies capable of capturing subtype evolution under therapeutic pressure. TNBC should therefore not be regarded as a single disease, but as a spectrum of biologically distinct and clinically evolving entities whose integrated characterization may be essential to improving outcomes in this historically poor-prognosis population.<\/jats:p>","DOI":"10.3390\/ijms27115040","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:50:28Z","timestamp":1780447828000},"page":"5040","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-9003","authenticated-orcid":false,"given":"Leonel","family":"Pekarek","sequence":"first","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-7855","authenticated-orcid":false,"given":"Cielo","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casanova-Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1708","authenticated-orcid":false,"given":"Miguel A.","family":"Ortega","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-6397","authenticated-orcid":false,"given":"\u00d3scar","family":"Fraile-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcala, 28801 Alcala de Henares, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Adrada, B.E., Moseley, T.W., Kapoor, M.M., Scoggins, M.E., Patel, M.M., Perez, F., Nia, E.S., Khazai, L., Arribas, E., and Rauch, G.M. (2023). Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. RadioGraphics, 43.","DOI":"10.1148\/rg.230034"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","article-title":"Molecular characterization of basal-like and non-basal-like triple-negative breast cancer","volume":"18","author":"Prat","year":"2013","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kesireddy, M., Elsayed, L., Shostrom, V.K., Agarwal, P., Asif, S., Yellala, A., and Krishnamurthy, J. (2024). Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 16.","DOI":"10.20944\/preprints202404.1138.v1"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hammersh\u00f8i Madsen, A.M., L\u00f8vendahl Eefsen, R.H., Nielsen, D., and K\u00fcmler, I. (2024). Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review. Breast J., 2024.","DOI":"10.1155\/2024\/9083055"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Collin, S.M., Hillman, S., Shah, C.H., Tank, R., Bhave, M., and Traina, T.A. (2026). Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study. JCO Oncol. Pract.","DOI":"10.1200\/OP-25-00822"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Li, C.H., Karantza, V., Aktan, G., and Lala, M. (2019). Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: A systematic literature review. Breast Cancer Res., 21.","DOI":"10.1186\/s13058-019-1210-4"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer\u2014The road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(14)71104-0","article-title":"Radiation therapy in the locoregional treatment of triple-negative breast cancer","volume":"16","author":"Moran","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-025-03197-w","article-title":"Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: An optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer","volume":"134","author":"Fujii","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","article-title":"Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial","volume":"25","author":"Fan","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, R.Q., Yan, L., Zhang, L., Ma, H.X., Wang, H.W., Bu, P., Xi, Y.F., and Lian, J. (2024). Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62991-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Richters, L., Gluz, O., Weber-Lassalle, N., Christgen, M., Haverkamp, H., Kuemmel, S., Kayali, M., Kates, R.E., Grischke, E.-M., and Altm\u00fcller, J. (2025). Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer. JAMA Netw. Open, 8.","DOI":"10.1001\/jamanetworkopen.2024.61639"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000494","article-title":"Triple-Negative Breast Cancer","volume":"27","author":"Nunnery","year":"2021","journal-title":"Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aine, M., Nacer, D.F., Arbajian, E., Veerla, S., Karlsson, A., H\u00e4kkinen, J., Johansson, H.J., Rosengren, F., Vallon-Christersson, J., and Borg, \u00c5. (2025). The DNA methylation landscape of primary triple-negative breast cancer. Nat. Commun., 16.","DOI":"10.1038\/s41467-025-58158-x"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Asleh, K., Riaz, N., and Nielsen, T.O. (2022). Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J. Exp. Clin. Cancer Res., 41.","DOI":"10.1186\/s13046-022-02476-1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20365","DOI":"10.1002\/cam4.6600","article-title":"Roles of long noncoding RNA in triple-negative breast cancer","volume":"12","author":"Das","year":"2023","journal-title":"Cancer Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"So, J.Y., Ohm, J., Lipkowitz, S., and Yang, L. (2022). Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharmacol. Ther., 237.","DOI":"10.1016\/j.pharmthera.2022.108253"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014Expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107, B., Temko, D., Stevens, L.E., Seehawer, M., Fassl, A., Murphy, K., Anand, J., Garza, K., Gulvady, A., and Qiu, X. (2023). Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Rep., 42.","DOI":"10.1016\/j.celrep.2023.113564"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xin, Y., Ma, Q., Deng, Q., Wang, T., Wang, D., and Wang, G. (2025). Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1521388"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Savas, P., Teo, Z.L., Lefevre, C., Flensburg, C., Caramia, F., Alsop, K., Mansour, M., A Francis, P., A Thorne, H., and Silva, M.J. (2016). The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program \u201cCASCADE\u201d. PLoS Med., 13, Erratum in PLoS Med. 2017, 14, e1002302. https:\/\/doi.org\/10.1371\/journal.pmed.1002204.","DOI":"10.1371\/journal.pmed.1002302"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lv, D., Lan, B., Guo, Q., Yi, Z., Qian, H., Guan, Y., Peng, X., Chen, T., and Ma, F. (2025). Exploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer. BMC Med., 23.","DOI":"10.1186\/s12916-025-03959-6"},{"key":"ref_30","first-page":"413","article-title":"Natural and chemotherapy-induced clonal evolution of tumors","volume":"82","author":"Ibragimova","year":"2017","journal-title":"Biochemistry"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Baskarane, H., Divakar, M.K., Batra, A., Kumar, A., Dubashi, B., Sehrawat, A., Kumar, P., Mishra, A., Tanwar, P., and Suhani, S. (2025). Mutational signature differences in paired tissues of triple-negative breast cancer receiving neoadjuvant therapy: Preliminary analysis. J. Clin. Oncol., 43.","DOI":"10.1200\/JCO.2025.43.16_suppl.e12555"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Devlin, K.L., Smith, R., Bucher, E., Dane, M., Bowman, C.L., Carlson, E.J., Kilburn, D., Sudar, D., Feiler, H.S., and Heiser, L.M. (2026). Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. Cell Rep., 45.","DOI":"10.1016\/j.celrep.2025.116826"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S1470-2045(25)00545-5","article-title":"Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): Updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial","volume":"26","author":"Yuan","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, D.-Y., Jiang, Z., Ben-David, Y., Woodgett, J.R., and Zacksenhaus, E. (2019). Molecular stratification within triple-negative breast cancer subtypes. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-55710-w"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Limsakul, P., Choochuen, P., Jungrungrueang, T., and Charupanit, K. (2024). Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031405"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Syrnioti, A., Timotheadou, E., Papadopoulos, V., Syrnioti, G., and Koletsa, T. (2025). Dissecting the Non-Immune Tumor Microenvironment in Triple-Negative Breast Cancer: Molecular Subtype-Specific Patterns and Prognostic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262211211"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., Colaprico, A., Silva, T.C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J.L., and Balko, J.M. (2021). Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-26502-6"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach","volume":"112","author":"Bareche","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.devcel.2019.03.026","article-title":"The extracellular matrix modulates the metastatic journey","volume":"49","author":"Kai","year":"2019","journal-title":"Dev. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Olsson, M., Larsson, P., Johansson, J., Sah, V.R., and Parris, T.Z. (2023). Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1237673"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mezi, S., Botticelli, A., Pomati, G., Cerbelli, B., Scagnoli, S., Amirhassankhani, S., D\u2019amati, G., and Marchetti, P. (2021). Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13051080"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., Jovanovi\u0107, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., E Sanders, M., and A Pietenpol, J. (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157368"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shome, R., Sen, P., Sarkar, S., and Ghosh, S.S. (2024). Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1\/P62 and Wnt\/\u03b2-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer. Exp. Cell Res., 438.","DOI":"10.1016\/j.yexcr.2024.114032"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/PAI.0000000000000897","article-title":"Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers","volume":"29","author":"Kumar","year":"2020","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Basho, R.K., Gilcrease, M., Murthy, R.K., Helgason, T., Karp, D.D., Meric-Bernstam, F., Hess, K.R., Herbrich, S.M., Valero, V., and Albarracin, C. (2017). Targeting the PI3K\/AKT\/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncol., 3.","DOI":"10.1001\/jamaoncol.2016.5281"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.18632\/oncotarget.27104","article-title":"Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer","volume":"10","author":"Colavito","year":"2019","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Bautista, R., Caro-S\u00e1nchez, C.H., Cabrera-Galeana, P., Alanis-Funes, G.J., Gutierrez-Mill\u00e1n, E., \u00c1vila-R\u00edos, S., Mat\u00edas-Florentino, M., Reyes-Ter\u00e1n, G., D\u00edaz-Ch\u00e1vez, J., and Villarreal-Garza, C. (2021). Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers, 13, Erratum in Cancers 2026, 18, 1627. https:\/\/doi.org\/10.3390\/cancers13246256.","DOI":"10.3390\/cancers18101627"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Syrnioti, A., Petousis, S., Newman, L.A., Margioula-Siarkou, C., Papamitsou, T., Dinas, K., and Koletsa, T. (2024). Triple Negative Breast Cancer: Molecular Subtype-Specific Immune Landscapes with Therapeutic Implications. Cancers, 16.","DOI":"10.3390\/cancers16112094"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rangel, N., Serrao, L., Capella, G., Orlando, G., Ragno, F., Rond\u00f3n-Lagos, M., Metovic, J., Cassoni, P., and Castellano, I. (2025). Surrogate molecular classification of LAR breast cancer in routine workflow. Endocr.-Relat. Cancer, 32.","DOI":"10.1530\/ERC-24-0316"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Asemota, S., Effah, W., Young, K.L., Holt, J., Cripe, L., Ponnusamy, S., Thiyagarajan, T., Hwang, D.-J., He, Y., and Mcnamara, K. (2023). Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype. Cell Rep., 42.","DOI":"10.1016\/j.celrep.2023.113461"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lee, M., Yoo, T.-K., Chae, B.J., Lee, A., Cha, Y.J., Lee, J., Ahn, S.G., and Kang, J. (2024). Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification. Sci. Rep., 14, Erratum in Sci. Rep. 2025, 15, 8225. https:\/\/doi.org\/10.1038\/s41598-024-61640-z.","DOI":"10.1038\/s41598-024-61640-z"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Khadela, A., Chavda, V.P., Soni, S., Megha, K., Pandya, A.J., and Vora, L. (2022). Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15010233"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","article-title":"Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): A multicentre, non-comparative, randomised, phase 2 trial","volume":"26","author":"Bonnefoi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.7150\/thno.36182","article-title":"Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts","volume":"10","author":"Coussy","year":"2020","journal-title":"Theranostics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/OTT.S379867","article-title":"Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far","volume":"16","author":"Stella","year":"2023","journal-title":"OncoTargets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","article-title":"Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann\u2019s Refined Classification","volume":"24","author":"Echavarria","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jiang, T., Shi, W., Wali, V.B., Pongor, L.S., Li, C., Lau, R., Gy\u0151rffy, B., Lifton, R.P., Symmans, W.F., and Pusztai, L. (2016). Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002193"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer\u2014How We Can Rise to the Challenge. Cells, 8.","DOI":"10.3390\/cells8090957"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Barchiesi, G., Roberto, M., Verrico, M., Vici, P., Tomao, S., and Tomao, F. (2021). Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.769280"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Egger, S.J., Chan, M.M.K., Luo, Q., and Wilcken, N. (2020). Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst. Rev., 10.","DOI":"10.1002\/14651858.CD013750"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wu, J., Yan, X., Fang, J., Peng, L., and Zhao, X. (2025). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: An updated systematic review and meta-analysis. Medicine, 104.","DOI":"10.1097\/MD.0000000000044740"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PPO.0000000000000499","article-title":"PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations","volume":"27","author":"Layman","year":"2021","journal-title":"Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ignatiadis, M., Bailey, A., McArthur, H., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S.Y., Dieterich, M., Perretti, T., and Shearer-Kang, E. (2025). Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA, 333.","DOI":"10.1001\/jama.2024.26886"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Chen, L., Li, H., Zhang, H., Yang, H., Qian, J., Li, Z., Ren, Y., Wang, S., Fu, P., and Yang, H. (2025). Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer. JAMA, 333.","DOI":"10.1001\/jama.2024.23560"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06665-6","article-title":"Clinical trials of immunotherapy in triple-negative breast cancer","volume":"195","author":"Howard","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","article-title":"Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer","volume":"31","author":"Agostinetto","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14737140.2023.2265059","article-title":"The role of immune checkpoint inhibition in triple negative breast cancer","volume":"23","author":"Tarekegn","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sriramulu, S., Thoidingjam, S., Speers, C., and Nyati, S. (2024). Present and Future of Immunotherapy for Triple-Negative Breast Cancer. Cancers, 16.","DOI":"10.20944\/preprints202408.1061.v1"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wesolowski, J., Tankiewicz-Kwedlo, A., and Pawlak, D. (2022). Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14163860"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Chai, R., Zhang, Z., Gong, Z., Li, Q., and Dong, C. (2025). Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1735893"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","article-title":"Immune-based combinations for metastatic triple negative breast cancer in clinical trials: Current knowledge and therapeutic prospects","volume":"31","author":"Rizzo","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Liu, Y., Hu, Y., Xue, J., Li, J., Yi, J., Bu, J., Zhang, Z., Qiu, P., and Gu, X. (2023). Advances in immunotherapy for triple-negative breast cancer. Mol. Cancer, 22, Erratum in Mol. Cancer 2023, 22, 154. https:\/\/doi.org\/10.1186\/s12943-023-01850-7.","DOI":"10.1186\/s12943-023-01850-7"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the Treatment of Androgen Receptor\u2013Expressing Triple-Negative Breast Cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zhao, Y.-X., Wang, H., Zhang, S.-W., Zhang, W.-X., Jiang, Y.-Z., and Shao, Z.-M. (2024). Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: Exploring chidamide and enzalutamide as a promising combination strategy. Cancer Cell Int., 24.","DOI":"10.1186\/s12935-024-03313-5"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chica-Parrado, M.R., Kim, G.M., Uemoto, Y., Napolitano, F., Lin, C.-C., Ye, D., Bikorimana, E., Fang, Y., Lee, K.-M., and Mendiratta, S. (2024). Combined inhibition of CDK4\/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer. Cancer Lett., 604, Erratum in Cancer Lett. 2025, 630, 217891. https:\/\/doi.org\/10.1016\/j.canlet.2024.217219.","DOI":"10.1016\/j.canlet.2025.217891"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lehmann, B.D., A Bauer, J., Schafer, J.M., Pendleton, C.S., Tang, L., Johnson, K.C., Chen, X., Balko, J.M., G\u00f3mez, H., and Arteaga, C.L. (2014). PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res., 16.","DOI":"10.1186\/s13058-014-0406-x"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Kono, M., Fujii, T., Lim, B., Karuturi, M.S., Tripathy, D., and Ueno, N.T. (2017). Androgen Receptor Function and Androgen Receptor\u2013Targeted Therapies in Breast Cancer. JAMA Oncol., 3.","DOI":"10.1001\/jamaoncol.2016.4975"},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2026, March 18). A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician\u2019s Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer. NCT06099769, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06099769."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1535-7163.MCT-23-0386","article-title":"Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor\u2013Positive Triple-Negative Breast Cancer by Inhibiting c-MYC\u2013mediated Tumorigenesis","volume":"24","author":"Xie","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hassan, A., and Aubel, C. (2025). The PI3K\/Akt\/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17132232"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: A review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Singh, J.C., Novik, Y., Stein, S., Volm, M., Meyers, M., Smith, J., Omene, C., Speyer, J., Schneider, R., and Jhaveri, K. (2014). Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res., 16.","DOI":"10.1186\/bcr3634"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","article-title":"A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II\/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"48206","DOI":"10.18632\/oncotarget.10195","article-title":"Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers","volume":"7","author":"Hatem","year":"2016","journal-title":"Oncotarget"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","article-title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer","volume":"189","author":"Dent","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","article-title":"Ipatasertib plus Paclitaxel for Patients with PIK3CA\/AKT1\/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial","volume":"30","author":"Dent","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2025.12.012","article-title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial","volume":"37","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clbc.2025.03.011","article-title":"Effects of AKT Inhibitors for PIK3CA\/AKT1\/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials","volume":"25","author":"Sano","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1535-7163.MCT-24-0693","article-title":"Depleting the Action of EZH2 through PI3K\u2013mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer","volume":"24","author":"Melino","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer","volume":"366","author":"Eidtmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Ma, X., Wang, X., Huang, J., Chen, Y., Zhang, J., Zhang, B., Shi, C., and Liu, L. (2016). Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160148"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Ding, X., Liang, J., Sharko, A.C., Hilimire, T.A., Li, J., Loskutov, J., Mack, Z.T., Ji, H., Schools, G.P., and Cai, C. (2024). Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors. Proc. Natl. Acad. Sci. USA, 121.","DOI":"10.1073\/pnas.2414501121"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Wen, W., Yost, S.E., Xing, Q., Yan, J., Han, E.S., Mortimer, J., and Yim, J.H. (2019). Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-43429-7"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"El Guerrab, A., Bamdad, M., Bignon, Y.-J., Penault-Llorca, F., and Aubel, C. (2020). Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63310-2"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Li, G., Hu, J., Cho, C., Cui, J., Li, A., Ren, P., Zhou, J., Wei, W., Zhang, T., and Liu, X. (2023). Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer. Cell. Signal., 109.","DOI":"10.1016\/j.cellsig.2023.110729"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bagegni, N.A., Nehring, L., Anderson, J., Haas, B., Luo, J., Trivedi, M.S., Kennedy, L.C., Bhave, M.A., Daily, K.C., and Razaq, W. (2022). A phase I\/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1128"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_106","first-page":"e235","article-title":"Antibody-Drug Conjugates in Triple Negative Breast Cancer","volume":"24","author":"Keskinkilic","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","article-title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial","volume":"33","author":"Liu","year":"2023","journal-title":"Cell Res."},{"key":"ref_108","unstructured":"ClinicalTrials.gov (2026, March 18). A Study of Famitinib Plus Camrelizumab and Chemotherapy in Advanced Triple-Negative Breast Cancer. NCT05760378, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05760378."},{"key":"ref_109","unstructured":"ClinicalTrials.gov (2026, March 18). A Study of VEGFR BP102 Plus Chemotherapy in Advanced Triple-Negative Breast Cancer. NCT05806060, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05806060."},{"key":"ref_110","unstructured":"ClinicalTrials.gov (2026, March 18). A Study of Everolimus Plus Chemotherapy in Advanced Triple-Negative Breast Cancer with PI3K\/AKT\/mTOR Pathway Alterations. NCT05954442, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05954442."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1634\/theoncologist.2019-0982","article-title":"Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance","volume":"25","author":"Zhao","year":"2020","journal-title":"Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Bouzid, R.S., Bouzid, R., Labed, H., Serhani, I., Hellal, D., Oumeddour, L., Boudhiaf, I., Ibrir, M., Khadraoui, H., and Belaaloui, G. (2025). Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13832-7"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Canino, F., Tornincasa, A., Bettelli, S., Manfredini, S., Barbolini, M., Moscetti, L., Omarini, C., Toss, A., Tamburrano, F., and Antonelli, G. (2024). Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052490"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/1878-0261.13671","article-title":"Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: Defining treatment targets and dynamic changes during disease progression","volume":"19","author":"Klocker","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): A multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/1878-0261.13091","article-title":"Multi-omic molecular profiling guide\u2019s efficacious treatment selection in refractory metastatic breast cancer: A prospective phase II clinical trial","volume":"16","author":"Pierobon","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Li, Y., Ma, J., Ma, X., Chen, C., Ruan, M., Yang, W., and Shui, R. (2024). PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping. Pathol.\u2014Res. Pract., 262.","DOI":"10.1016\/j.prp.2024.155556"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jnci\/djad154","article-title":"Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer","volume":"115","author":"Wang","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s12094-023-03203-8","article-title":"SEOM\u2013GEICAM\u2013SOLTI clinical guidelines in advanced breast cancer (2022)","volume":"25","author":"Blancas","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.02.027","article-title":"BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer","volume":"450","author":"Solinas","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-024-07561-x","article-title":"Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: Results from a population-based cohort","volume":"210","author":"Sigurjonsdottir","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Masuda, H., Harano, K., Miura, S., Wang, Y., Hirota, Y., Harada, O., Jolly, M.K., Matsunaga, Y., Lim, B., and Wood, A.L. (2022). Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis. Oncol., 6.","DOI":"10.1200\/PO.20.00368"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"van Geelen, C.T., Savas, P., Teo, Z.L., Luen, S.J., Weng, C.-F., Ko, Y.-A., Kuykhoven, K.S., Caramia, F., Salgado, R., and Francis, P.A. (2020). Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res., 22, Erratum in Breast Cancer Res. 2022, 24, 50. https:\/\/doi.org\/10.1186\/s13058-020-01328-0.","DOI":"10.1186\/s13058-022-01539-7"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5040\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:23:32Z","timestamp":1780979012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":124,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115040"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115040","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}